000285032 001__ 285032
000285032 005__ 20260206165952.0
000285032 0247_ $$2doi$$a10.1080/21678421.2025.2557932
000285032 0247_ $$2pmid$$apmid:40932199
000285032 0247_ $$2ISSN$$a2167-8421
000285032 0247_ $$2ISSN$$a2167-9223
000285032 037__ $$aDZNE-2026-00157
000285032 041__ $$aEnglish
000285032 082__ $$a610
000285032 1001_ $$00000-0001-9471-7798$$aSpittel, Susanne$$b0
000285032 245__ $$aDextromethorphan/quinidine (DMQ) for reducing bulbar symptoms in amyotrophic lateral sclerosis - assessment of treatment experience in a multicenter study.
000285032 260__ $$aAbingdon$$bTaylor Francis Group$$c2026
000285032 3367_ $$2DRIVER$$aarticle
000285032 3367_ $$2DataCite$$aOutput Types/Journal article
000285032 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1770393387_713
000285032 3367_ $$2BibTeX$$aARTICLE
000285032 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285032 3367_ $$00$$2EndNote$$aJournal Article
000285032 520__ $$aIn amyotrophic lateral sclerosis (ALS), dextromethorphan/quinidine (DMQ) has been reported to reduce bulbar symptoms, including dysarthria and dysphagia. However, data on patients' perceptions of DMQ treatment are limited.Data on DMQ treatment were collected from 1065 ALS patients treated at 13 ALS centers between 10-2015 and 06-2025. Patient-reported outcome measures (PROM) of 179 participants were remotely assessed via the 'ALS App'. PROM included the self-explanatory version of the ALS Functional Rating Scale (ALSFRS-R-SE), the Net Promoter Score (NPS); and Treatment Satisfaction Questionnaire for Medication (TSQM-9).Mean disease duration was 29.3 months (SD 38.1). ALS progression before treatment was 0.82 points/month (ALSFRS-R). Mean DMQ treatment duration was 8.4 months (SD 10.8), including 35.2% (n = 374) of shorter (<3 months), 35.3% (n = 375) of longer (3-9 months), and 29.5% (n = 313) of very long DMQ treatment (>9 months). Patients' recommendation (n = 178) was positive (NPS: +23) with higher scores after very long DMQ treatment (NPS +37) compared to longer (NPS +15) and shorter treatment (NPS +7.5), respectively. TSQM-9 scores (n = 163) demonstrated high satisfaction for effectiveness 60.0 (SD 25.9), convenience 73.8 (SD 18.2), and global satisfaction 63.4 (SD 29.8).The positive perception in PROM underscores the value of DMQ as an individualized treatment option for bulbar symptoms in ALS. However, shortage of clinical data, online assessment, and selection biases are among the limitations of this study that need to be addressed in further investigations.
000285032 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000285032 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000285032 650_7 $$2Other$$aAmyotrophic lateral sclerosis
000285032 650_7 $$2Other$$abulbar symptoms
000285032 650_7 $$2Other$$adextromethorphan/quinidine (DMQ)
000285032 650_7 $$2Other$$adysarthria
000285032 650_7 $$2Other$$adysphagia
000285032 650_7 $$2Other$$apatient-reported outcomes
000285032 650_7 $$07355X3ROTS$$2NLM Chemicals$$aDextromethorphan
000285032 650_7 $$0ITX08688JL$$2NLM Chemicals$$aQuinidine
000285032 650_7 $$2NLM Chemicals$$adextromethorphan - quinidine combination
000285032 650_7 $$2NLM Chemicals$$aDrug Combinations
000285032 650_2 $$2MeSH$$aHumans
000285032 650_2 $$2MeSH$$aDextromethorphan: therapeutic use
000285032 650_2 $$2MeSH$$aAmyotrophic Lateral Sclerosis: drug therapy
000285032 650_2 $$2MeSH$$aAmyotrophic Lateral Sclerosis: complications
000285032 650_2 $$2MeSH$$aMale
000285032 650_2 $$2MeSH$$aFemale
000285032 650_2 $$2MeSH$$aMiddle Aged
000285032 650_2 $$2MeSH$$aQuinidine: therapeutic use
000285032 650_2 $$2MeSH$$aAged
000285032 650_2 $$2MeSH$$aPatient Reported Outcome Measures
000285032 650_2 $$2MeSH$$aDrug Combinations
000285032 650_2 $$2MeSH$$aTreatment Outcome
000285032 650_2 $$2MeSH$$aPatient Satisfaction
000285032 650_2 $$2MeSH$$aAdult
000285032 7001_ $$aGrehl, Torsten$$b1
000285032 7001_ $$0P:(DE-2719)9001116$$aWeydt, Patrick$$b2$$udzne
000285032 7001_ $$aKettemann, Dagmar$$b3
000285032 7001_ $$aFabian, Rachel$$b4
000285032 7001_ $$aRödiger, Annekathrin$$b5
000285032 7001_ $$aSmesny, Uta$$b6
000285032 7001_ $$aSteinbach, Robert$$b7
000285032 7001_ $$aIlse, Benjamin$$b8
000285032 7001_ $$aWeyen, Ute$$b9
000285032 7001_ $$aPetri, Susanne$$b10
000285032 7001_ $$aLumi, Rea$$b11
000285032 7001_ $$aBjelica, Bogdan$$b12
000285032 7001_ $$0P:(DE-2719)2812561$$aLingor, Paul$$b13$$udzne
000285032 7001_ $$aGrosskreutz, Julian$$b14
000285032 7001_ $$aGöricke, Bettina M$$b15
000285032 7001_ $$aPfeilschifter, Waltraud$$b16
000285032 7001_ $$aSchmeja, Wibke$$b17
000285032 7001_ $$0P:(DE-2719)9001951$$aDorst, Johannes$$b18$$udzne
000285032 7001_ $$aMensch, Alexander$$b19
000285032 7001_ $$aSiebert, Jürgen$$b20
000285032 7001_ $$aNorden, Jenny$$b21
000285032 7001_ $$0P:(DE-2719)9000485$$aBernsen, Sarah$$b22$$udzne
000285032 7001_ $$00000-0001-6853-9895$$aSubramanian, Senthil Kumar$$b23
000285032 7001_ $$aHildebrandt, Barbara$$b24
000285032 7001_ $$aWalter, Bertram$$b25
000285032 7001_ $$aMünch, Christoph$$b26
000285032 7001_ $$00000-0003-2473-4116$$aMaier, André$$b27
000285032 7001_ $$00000-0002-2736-7350$$aMeyer, Thomas$$b28
000285032 773__ $$0PERI:(DE-600)2705061-0$$a10.1080/21678421.2025.2557932$$gVol. 27, no. 1-2, p. 185 - 197$$n1-2$$p185 - 197$$tAmyotrophic lateral sclerosis & frontotemporal degeneration$$v27$$x2167-8421$$y2026
000285032 8564_ $$uhttps://pub.dzne.de/record/285032/files/DZNE-2026-00157.pdf$$yRestricted
000285032 8564_ $$uhttps://pub.dzne.de/record/285032/files/DZNE-2026-00157.pdf?subformat=pdfa$$xpdfa$$yRestricted
000285032 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001116$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000285032 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2812561$$aExternal Institute$$b13$$kExtern
000285032 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001951$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b18$$kDZNE
000285032 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9000485$$aExternal Institute$$b22$$kExtern
000285032 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000285032 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bAMYOTROPH LAT SCL FR : 2022$$d2025-01-01
000285032 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-01
000285032 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-01
000285032 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-01
000285032 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-01
000285032 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-01
000285032 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-01
000285032 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-01
000285032 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-01
000285032 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-01
000285032 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-01-01
000285032 9201_ $$0I:(DE-2719)1011001$$kClinical Research (Bonn)$$lClinical Research Coordination$$x0
000285032 9201_ $$0I:(DE-2719)5000077$$kClinical Study Center (Ulm)$$lClinical Study Center (Ulm)$$x1
000285032 980__ $$ajournal
000285032 980__ $$aEDITORS
000285032 980__ $$aVDBINPRINT
000285032 980__ $$aI:(DE-2719)1011001
000285032 980__ $$aI:(DE-2719)5000077
000285032 980__ $$aUNRESTRICTED